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Technologies for reprogramming cells are spreading like wildfire. One laboratory after another is reporting faster, more
efficientmethods for generating cardiomyocytes, blood cells, and even neurons, all from readily available skin fibroblasts.
But how close are these ‘‘custom-made’’ cells to reaching the clinic? This Select highlights recent studies demonstrating
the ability of cultured stem cells to repopulate and regenerate damaged organs in vivo while also offering a glimpse of
future challenges on the horizon.Human iPSC-derived hepatocytes engraft
and regenerate a damaged liver in a mouse.
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Liver diseases are prime candidates for alternative stem cell-based therapies. The
need for liver transplants far exceeds the number of available organs, and liver cell
progenitors are difficult to isolate from donors and maintain in culture. Previous
research successfully generated human hepatocytes and their precursors from
induced pluripotent stem cells (iPSCs), potentially offering an unlimited source of liver
cell progenitors. But do these cells retain their regenerative capacity when trans-
planted into a host?
Now, Liu et al. (2011) demonstrate that, indeed, liver cells derived from human iPSCs
repopulate an injured mouse liver and repair the tissue at levels comparable to cells
derived from embryonic stem cells (ESCs) or primary human hepatocytes. To allow
the engraftment of human cells into mice, the authors use a mouse line with a severely
compromised immune system (i.e., it lacks mature T cells, B cells, natural killer cells,
and normal cytokine signaling). They then mimic cirrhosis by treating the mice for
4 weeks with dimethylnitrosamine, a carcinogen that is especially harmful to the liver.
When they inject human iPSC-derived hepatic cells into the animals’ blood, the cells
differentiate into mature and functional hepatocyte-like cells with comparable engraft-
ment efficiencies as primary human hepatocytes (9%–15% versus 11%, respectively).Most importantly, transplantationwith either cell type increases survival of the animals by50%. Liu and colleagues then examine the
transplantation potential of iPSC-derived hepatocytes originating fromeach of the three different germ layer tissues: ectoderm, endo-
derm, andmesoderm. Although each iPSC line displays a distinct methylation pattern on its genome, all three cell types show similar
propensity to differentiate into hepatocytes and then engraft and repair liver tissue in vivo. These results suggest that small phenotypic
variations in iPSC-derived cells may not be a major issue for regenerative applications.
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Even after 7 months, Liu et al. saw no signs of tumor formation in the
animals transplantedwith iPSC-derived hepatocytes. However, onemajor
disadvantage of using iPSCs for regenerative therapies is their high
propensity for tumorigenesis. Now, Huang et al. (2011) circumvent this
challenge by avoiding the pluripotent state altogether. They directly
convert mouse skin cells into hepatocytes and then demonstrate that
these ‘‘transdifferentiated’’ cells repopulate and repair damaged livers of
mice in vivo.
Primary liver cells are difficult to maintain in culture, but hepatocytes
without the tumor suppressor p19ARF are known to proliferate in vitro while
still maintaining their genetic stability. Thus, the authors cleverly start off
with p19ARF-mutant fibroblasts. When they overexpress 14 transcription
factors known to be critical for liver development, the p19ARF-mutant fibro-
blasts transform into hepatocyte-like cells, or ‘‘iHeps.’’ The authors thennarrow the required reprogramming factors down to three: overexpression of Gata4, Hnf1a, and Foxa3, together with inactivation
of p19ARF. The global gene expression profiles for iHeps are similar to those of cultured hepatocytes, and iHeps behave like liver cells.
They import low-density lipoprotein, break down toxins, and produce proteins that are specific to mature hepatocytes (i.e., cyto-
chrome P450 enzymes), suggesting that the reprogramming process does not pass through a progenitor-like state.
Finally, the authors test the therapeutic potential of the iHeps by injecting them into a mouse model of liver failure. Five of the 12
mice that receive the reprogrammed cells were still alive 8 weeks after treatment, compared to 0 of 10 control mice. Although trans-
plantation with primary hepatocytes rescues almost all treated mice, the livers regenerated by iHeps appear healthy and normal.
Furthermore, 2 months after transplantation, Huang and colleagues observe no signs of tumor formation in the mice but instead
find that the iHeps lose their proliferation capacity. Clearly, directly reprogrammed hepatocytes represent a powerful new source
of liver cells for disease modeling, transplantation, and tissue engineering.
Huang, P., et al. (2011). Nature. Published online May 11, 2011. 10.1038/nature10116.Cell 146, July 8, 2011 ª2011 Elsevier Inc. 5
Regenerated mouse lung with a human bronchiole (left) and
alveoli (right), expressing EGFP and the epithelial marker
pan-CK. Image courtesy of P. Anversa.
Chimeric mice made with episomal
iPSCs. Image courtesy of Y. Xu.Exhale. Lung Stem Cells Have Arrived
Compared to the liver, the lung has lagged far behind en route to stem
cell-based treatments. One major reason is the conspicuous absence
of human cells that are capable of generating all tissues of the lung,
such as the airways, epithelial glands, and alveoli. In fact, the current
view is that specialized progenitor cells maintain and repair each of
these lung domains. Now, Kajstura et al. (2011) challenge this dogma
by identifying a distinct pool of cells in human airways, which are self-
renewing and multipotent. Most impressively, these cells can incorpo-
rate into and rebuild a damaged mouse lung. Could they be the long-
awaited lung stem cells?
Using an immuno-sorting strategy, Kajstura et al. first find cells
in human lung samples, which express the receptor c-kit. This tyrosine
kinase receptor binds to cytokine stem cell factor and is expressed on
multipotent cardiomyocytes and hematopoietic stem cells. However,
Kajstura et al. find that, under identical conditions, c-kit-expressing
lung and heart cells uniquely differentiate into lung epithelial cells
and cardiomyocytes, respectively, suggesting that they are distinctcell types. The authors then show that the c-kit-expressing lung cells can divide symmetrically and asymmetrically, and they express
high levels of four key pluripotent factors:NANOG,OCT3/4,SOX2, andKLF4. Next, Kajstura and colleagues examine how these cells
behave in vivo by injecting them near damaged regions of mice lungs. After 10–14 days, the c-kit-expressing cells generate amouse-
human lung chimera by developing human bronchioles, alveoli, and pulmonary vessels. Although these structures integrate with the
recipient mouse lung, future studies are required to determine their functionality. Nevertheless, the key conclusion of this landmark
study—that human lungs harbor cells that are capable of self-organizing into complete respiratory units—undoubtedly will launch
lung bioengineering into a new era and will rejuvenate efforts toward regenerative therapies for respiratory disorders.
Kajstura, J., et al. (2011). N. Engl. J. Med. 364, 1795–1806.iPSCs: Rejected after Review
In the three studies above, cultured stem cells were transplanted into animals with
severely compromised immune systems, allowing the engraftment of human cells in
mice. But what happens in transplant recipients with normal immune systems? Will re-
programmed cells successfully engraft if they have the same genetic background as
a patient? Now Zhao et al. (2011) show that, at least for transplanted iPSCs, the answer
is a surprising ‘‘no’’; tumors formed by injected iPSCs trigger an immune response in
mice, and some iPSCs are rejected immediately.
To test the immune reactivity of iPSCs, Zhao et al. take advantage of the fact that both
ESCs and iPSCs generate a special type of tumor called a teratoma (which contains
differentiated cells from all three germ layers). When they inject mice with ESCs that genet-
ically match the animals, the cells easily form teratomas but do not trigger an immune
response. The authors then use two strategies to generate iPSCs from mouse embryonic
fibroblasts: they express reprogramming factors (Oct4, Sox2, and Klf4) either by retroviral
integration into the genome (the ‘‘classic approach’’) or from a transient vector that does
not integrate into the genome, an ‘‘episome.’’ When injected into the animals, the ‘‘classic’’
iPSCs formvery few teratomas ingeneticallymatchedmice, and the tumors that doarise are
subsequently attacked by T cell infiltration and necrosis. In contrast, the episomaliPSCs, which often lose their expression vector, are strikingly less immunogenic; they efficiently form teratomas with dramatically
less necrosis (10%). Interestingly, gene expression profiles indicate that dozens of genes are abnormally expressed in the iPSC-
derived teratomas, and overexpressing three of them (Hormad1, Zg16, and Cyp3a11) dramatically reduces the ESCs’ ability to form
teratomas upon transplant. Thus, although iPSC-derived cells may be more immune reactive than first appreciated, these results
suggest that this challenge may be overcome by optimizing reprogramming regimes.
Zhao, T., et al. (2011). Nature 474, 212–215.
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